Loading provider…
Loading provider…
Surgery Physician in Philadelphia, PA
NPI: 1194934299Primary Practice Location
THOMAS JEFFERSON UNIVERSITY HOSPITAL
900 Walnut St, Philadelphia, PA
Primary Employer
Jefferson University Physicians
jeffersonhealth.org
HQ Phone
Get MD Joshua's Phone Numberphone_androidMobile
Get MD Joshua's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 113 | 162 |
| 2 | 99291Critical care delivery critically ill or injured patient, first 30-74 minutes | 47 | 106 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 41 | 53 |
| 4 | 99231Subsequent hospital inpatient care, typically 15 minutes per day | 38 | 52 |
| 5 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 35 | 35 |
Authors: Nagata, Katsuhiro, Suto, Yujin, Cognetti, John, Browne, Kevin D, Kumasaka, Kenichiro, Johnson, Victoria E, Kaplan, Lewis, Marks, Joshua, Smith, Douglas H, Pascual, Jose L
Journal: J Trauma Acute Care Surg
Authors: Bilal Nasim, Zachary Callahan, Jeffrey Sutton, Christopher Stahl, Mary Kimbrough, Samuel Campbell, Stephen Stopenski, Jeffry Nahmias, Katherine Meister, Leah Winer, Robert Martin, Ali Elsaadi, Brian George, Shah-Jahan Dodwad, Motaz Al Yafi, Sasha Adams, Deborah Farr
Journal: Ann Surg
Publication Date: 2023-03-30
Safety of early tracheostomy in trauma patients after anterior cervical fusion.
Authors: Murray Cohen
Journal: J Trauma Acute Care Surg
Lead Sponsor: Atox Bio Ltd
Intervention / Treatment: DRUG: Placebo, DRUG: Reltecimod 0.5 mg/kg
Lead Sponsor: Atox Bio Ltd
Collaborators: Biomedical Advanced Research and Development Authority
Intervention / Treatment: DRUG: AB103 0.5 mg/kg, OTHER: NaCl 0.9%